ArticleWorld journal of gastroenterology2001
TECA hybrid artificial liver support system in treatment of acute liver failure.
Article in World journal of gastroenterology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 44 citations in OpenAlex.
- Effects of hemoperfusion adsorption and/or plasma exchange in treatment of severe viral hepatitis: a comparative study.World journal of gastroenterology · 2004Trial
- Establishment of a risk assessment score for deep vein thrombosis after artificial liver support system treatment.World journal of clinical cases · 2021Article
- Posthepatectomy liver failureTurkish journal of medical sciences · 2020Review
- End-stage liver failure: filling the treatment gap at the intensive care unit.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2020Review
- Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure.The Journal of international medical research · 2020Article
- Systematic review: extracorporeal bio-artificial liver-support system for liver failure.Hepatology international · 2012Article
- Clinical usefulness of measuring red blood cell distribution width in patients with hepatitis B.PloS one · 2012Article
- A theoretical approach to zonation in a bioartificial liver.Biotechnology and bioengineering · 2012Article
- Extracorporeal bioartificial liver for treating acute liver diseases.The journal of extra-corporeal technology · 2011Review
- Liver Cell Culture Devices.Cell medicine · 2010Article
- Clinical application of bioartificial liver support systems.Annals of surgery · 2004Review
- Cryopreservation and gel collagen culture of porcine hepatocytes.World journal of gastroenterology · 2004Article
- TECA hybrid artificial liver support system in treatment of acute liver failure.World journal of gastroenterology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess the efficacy and safety of TECA type hybrid artificial liver support system (TECA-HALSS) in providing liver function of detoxification, metabolism and physiology by treating the patients with acute liver failure (ALF).
methodsThe porcine liver cells (1-2) x 10(10) were separated from the Chinese small swine and cultured in the bioreactor of TECA-BALSS at 37.0 degrees C and circulated through the outer space of the hollow fiber tubes in BALSS. The six liver failure patients with various degree of hepatic coma were treated by TECA-HALSS and with conventional medicines. The venous plasma of the patients was separated by a plasma separator and treated by charcoal adsorbent or plasma exchange. The plasma circulated through the inner space of the hollow fiber tubes of BALSS and mixed with the patients' blood cells and flew back to their blood circulation. Some small molecular weight substances were exchanged between the plasma and porcine liver cells. Each treatment lasted 6.0-7.0 h. Physiological and biochemical parameters were measured before,during and after the treatment.
resultsThe average of porcine liver cells was (1.0-3.0) x 10(10) obtained from each swine liver using our modified enzymatic digestion method. The survival rate of the cells was 85%-93% by trypan blue stain and AO/PI fluorescent stain. After cultured in TECA-BALSS bioreactor for 6 h, the survival rate of cells still remained 70%-85%. At the end of TECA-HALSS treatment, the levels of plasma NH(3), ALT, TB and DB were significantly decreased. The patients who were in the state of drowsiness or coma before the treatment improved their appetite significantly and regained consciousness, some patients resumed light physical work on a short period after the treatment. One to two days after the treatment, the ratio of PTA increased warkedly. During the treatment, the heart rates, blood pressure, respiration condition and serum electrolytes (K(+), Na(+) and Cl(-)) were stable without thrombosis and bleeding in all the six patients.
conclusionTECA-HALSS treatment could be a rapid, safe and efficacious method to provide temporary liver support for patients with ALF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.